Rep. Robert Bresnahan, Jr. Sells Humana Inc. (NYSE:HUM) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Humana Inc. NYSE: HUM. In a filing disclosed on June 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Humana stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zoom Communications NASDAQ: ZM on 6/25/2025.
• Purchased $1,001 - $15,000 in shares of Coinbase Global NASDAQ: COIN on 6/24/2025.
• Purchased $1,001 - $15,000 in shares of Circle Internet Group NYSE: CRCL on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 6/23/2025.
• Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 6/13/2025.
• Sold $1,001 - $15,000 in shares of Atlassian NASDAQ: TEAM on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of ServiceTitan NASDAQ: TTAN on 6/11/2025.
• Sold $1,001 - $15,000 in shares of Datadog NASDAQ: DDOG on 6/11/2025.
• Sold $1,001 - $15,000 in shares of GitLab NASDAQ: GTLB on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/11/2025.

Humana Trading Up 3.9%

Humana stock traded up $9.01 during midday trading on Friday, hitting $238.22. 1,569,145 shares of the stock were exchanged, compared to its average volume of 1,505,668. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $406.09. The stock has a market capitalization of $28.75 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 1.57 and a beta of 0.44. The stock's 50-day simple moving average is $234.56 and its 200 day simple moving average is $256.27. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a net margin of 1.42% and a return on equity of 14.47%. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. During the same period last year, the business earned $7.23 earnings per share. Humana's revenue was up 8.4% compared to the same quarter last year. On average, equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HUM shares. Truist Financial cut their price objective on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Wall Street Zen raised shares of Humana from a "hold" rating to a "buy" rating in a research note on Sunday, July 20th. Wells Fargo & Company set a $348.00 target price on shares of Humana in a research note on Friday, July 18th. Robert W. Baird decreased their price objective on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Sixteen analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Humana presently has an average rating of "Hold" and an average price target of $282.43.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. NorthRock Partners LLC lifted its stake in Humana by 199.6% in the second quarter. NorthRock Partners LLC now owns 2,394 shares of the insurance provider's stock worth $585,000 after acquiring an additional 1,595 shares during the last quarter. Atria Wealth Solutions Inc. lifted its stake in Humana by 10.3% in the second quarter. Atria Wealth Solutions Inc. now owns 955 shares of the insurance provider's stock worth $234,000 after acquiring an additional 89 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in Humana by 112.3% in the second quarter. Sequoia Financial Advisors LLC now owns 3,790 shares of the insurance provider's stock worth $927,000 after acquiring an additional 2,005 shares during the last quarter. Pzena Investment Management LLC lifted its stake in Humana by 6.5% in the second quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider's stock worth $996,664,000 after acquiring an additional 247,744 shares during the last quarter. Finally, Leith Wheeler Investment Counsel Ltd. lifted its stake in Humana by 661.7% in the second quarter. Leith Wheeler Investment Counsel Ltd. now owns 1,038,703 shares of the insurance provider's stock worth $253,942,000 after acquiring an additional 902,340 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.